tirzepatide harrisburg nc FDA says years-long tirzepatide shortage

As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), tirzepatide produces synergistic effects like increased insulin production and release, which gives it an edge over strict GLP-1 receptor agonist such as semaglutide (Ozempic)

Given the molecular weight and structure, some excretion into breast milk likely occurs

This is exactly why ongoing monitoring is essentialprevention is the goal

Weight management can be a challenging journey for many adults

Need help deciding

In the interim, continued shared decision making with patients and clinical vigilance for pancreatic diseases in patients on GLP-1RA therapy remains prudent